The White House has released a science agenda it brands a "Golden Age" plan for US research — and the plan's central weakness, according to a critique published by The Scientist, is what it leaves out: the mechanisms that actually made American science dominant.

The critique's core argument is direct. Decades of US leadership in biomedical and physical research rest on sustained federal funding, investigator-initiated science, open international collaboration and institutional independence. The new plan, as summarized by the publication, does not engage with any of these foundations.

What does the plan actually propose?

The Scientist frames the "Golden Age" initiative as a vision statement rather than an operational research policy. According to the critique, the plan leans on rhetoric about restoring American scientific preeminence while remaining silent on the plumbing underneath: grant structures, peer review, university research budgets and the training pipeline that supplies laboratories with talent.

For R&D managers at universities, institutes and vendors, that omission matters. Portfolio planning — multi-year instrument purchases, staff hiring, clinical trial scheduling — depends on predictable federal appropriations and stable agency priorities. A plan that celebrates outcomes without addressing inputs gives procurement and hiring committees nothing to model against.

Which success factors does the critique say are missing?

The Scientist's assessment identifies several historical pillars of US science that the plan does not credit or protect:

• Sustained public funding of basic research, the layer that industry rarely finances because payoffs are distant and uncertain.
• Openness to international talent, which has long filled US graduate programs and lab benches.
• Investigator-driven inquiry, where scientists rather than political priorities set the research agenda.
• Institutional autonomy, insulating science agencies and universities from directional political interference.

The publication argues that a strategy ignoring these elements risks managing the appearance of scientific greatness rather than its substance. No specific funding figures, agency reorganizations or program timelines appear in the critique's summary of the plan, which itself signals how thin the operational content is.

Why does this matter for research managers now?

The critique lands at a moment when US research institutions are already absorbing turbulence: budget uncertainty, policy shifts affecting international researchers, and questions about the independence of federal science agencies. The Scientist's charge is that the "Golden Age" framing papered over these pressures rather than resolving them.

The implied warning for lab directors and R&D portfolio leads is procedural. If the administration's plan does not specify appropriations, hiring pathways or collaboration frameworks, then the risk models institutions build should assume continued volatility rather than the stability the plan's title implies.

The critique also functions as a benchmark. Any future White House research strategy can now be measured against the checklist the article effectively constructs: does it fund basic research, does it welcome global talent, does it preserve investigator autonomy, does it respect institutional independence. Plans that fail those tests, The Scientist suggests, are not plans for a golden age but for managed decline.

The publication's closing position is that the ingredients of US scientific success are documented and reproducible — and that the current plan's failure to name them is the clearest sign it has not engaged with how the enterprise actually works. Whether the administration revises the agenda to address those gaps will determine whether "Golden Age" becomes a policy framework or a slogan.